Medicinal chemistry of 2,2,4-substituted morpholines

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3422-3430

  Rekka, E A ^a   Kourounakis, P N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Analgesics; Antioxidants; Atherosclerosis; Dyslipidemia; Inflammation; Morpholines; Structure activity relationships; Synthesis

Indexed keywords

1,4 OXAZINE DERIVATIVE; 2 (3 NITROXY)PROPOXY 2 BIPHENYL 4 METHYLMORPHOLINE; 2 (4 BIPHENYL) 2 (3 NITROXY)PROPOXY 4 METHYLMORPHOLINE; 2 BIPHENYL DERIVATIVE; 2 PHENYL DERIVATIVE; 2,2,4 MORPHOLINE DERIVATIVE; 3 PHENYL 3 N PROPOXY OCTAHYDRO[2,3 C]OXAZINE; AMINOKETONE; BROMOMETHYLKETONE DERIVATIVE; CHOLESTEROL; ETHANOLAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MORPHOLINE DERIVATIVE; NALOXONE; OCTAHYDRO 2 HYDROXY 2 BIPHENYL 4 METHYL 2H BENZO[B][1,4]OXAZINE; PETHIDINE; SQUALENE SYNTHASE INHIBITOR; STYRENE DERIVATIVE; TETRAHYDRO 1,4 OXAZINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMISTRY; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; DYSLIPIDEMIA; IONIZATION; LIPOPHILICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77957938965     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176276     Document Type: Article

References (45)

1. Bettoni, G.; Franchini, C.; Perrone, R.; Tortorella, V. Synthesis and absolute configuration of substituted morpholines. Tetrahedron, 1980, 36, 409-415.
2. Wei-Yang S; LeBas, C.L.; Kopecky, A.C.; Knifton, J.F. Ruthenium-catalyzed synthesis of substituted 2-hydroxymorpholines and substituted morpholines. Tetrahedron Lett., 1992, 33, 871-874.
3. Tiecco, M.; Testaferri, L.; Marini, F.; Sternativo, S.; Santi, C.; Bagnoli, L.; Temperini, A. Selenium-promoted synthesis of enanti- omerically pure substituted morpholines starting from alkenes and chiral aminoalcohols. Tetrahedron Asymmetry, 2003, 14, 2651-2657.
4. Lupi, V.; Albanese, D.; Landini, D.; Scaletti, D.; Penso, M. Synthe- sis of 2,6-disubstituted morpholines through regioselective oxiranes ring opening by tosylamide under PTC conditions. Tetrahedron, 2004, 60, 11709-11718.
5. Agejas, J.; Lamas, C. Straightforward synthesis of (R,R/S,S)-2-[2- (2-aryl)-1-phenyl-ethyl]-morpholines: a new class of inhibitors of the norepinephrine transporter. Tetrahedron Lett., 2007, 48, 2603-2605.
6. Xu, W.; Gray, D.L. Shelly A. Glase, S.A; Barta, N.S. Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5550-5553.
7. Letavic, M.A.; Keith, J.M.; Ly, K.S.; Bonaventure, P.; Feinstein, M.A.; Lord, B.; Miller, K.L.; Motley, S.T.; Nepomuceno, D.; Sutton, S.W.; Carruthers, N.I. 2-Aryloxymethylmorpholine histamine H3 antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 5796-5799.
8. Menear, K.A.; Gomez, S.; Malagu, K.; Bailey, C.; Blackburn, K.; Cockcroft, X.L.; Ewen, S.; Fundo, A.; Le Gall, A.; Hermann, G.; Sebastian, L.; Sunose, M.; Presnot, T.; Torode, E.; Hickson, I.; Martin, N.M.B.; Smith, G.C.M.; Pike, K.G. Identification and optimisation of novel and selective small molecular weight kinase in- hibitors of mTOR. Bioorg. Med. Chem. Lett., 2009, 19, 5898-5901.
9. Josien, H.; Bara, T.; Rajagopalan, M.; Clader, J.W.; Greenlee, W.J.; Favreau, L.; Hyde, L.A.; Nomeir, A.A.; Parker, E.M.; Song, L.; Zhang, L.; Zhang, Q. Novel orally active morpholine N- arylsulfonamides c-secretase inhibitors with low CYP 3A4 liability. Bioorg. Med. Chem. Lett., 2009, 19, 6032-6037.
10. Beckett, A.H.; Hunter, W.H.; Kourounakis, P. Synthesis and pharmacological action of some N-alkyl morpholines and their salts. J. Pharm. Pharmacol., 1968, 20, 218S.
11. Rekka, E.; Kourounakis, P. Synthesis, physicochemical properties and biological studies of some substituted 2-alkoxy-4-methylmorpholines. Eur. J. Med. Chem., 1989, 24, 179-184.
12. Chrysselis, M.C.; Rekka, E.A.; Siskou, I.C.; Kourounakis, P.N. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J. Med. Chem., 2002, 45, 5406-5409.
13. Kourounakis P.; Hunter, W.H.; Morris, P.G. Bridgehead N,O- heterocycles of biological interest. Arzneim.-Forsch./Drug Res., 1979, 7, 983-986
14. Henchoz, Y.; Bard, B.; Guillarme, D.; Carrupt, P.A.; Veuthey, J.L.; Martel, S. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution. Anal. Bioanal. Chem., 2009, 394, 707-729.
15. Beckett, A.H.; Kourounakis, P. The relationship between chemical structure and basicity in some morpholine compounds. Arzneim. Forsch. Drug Res., 1976, 26, 1810-1811.
16. Mannhold, R.; Rekker, R.F. The hydrophobic fragmental constant approach for calculating log P in octanol/water and aliphatic hydrocarbon/water systems. Persp. Drug Disc. Des., 2000, 18, 1-18.
17. Leo, A.J. Some advantages of calculating octanol-water partition coefficients. J. Pharm. Sci., 1987, 76, 166-168.
18. Bard, B.; Carrupt, P.A.; Martel, S. Lipophilicity of basic drugs measured by hydrophilic interaction chromatography J. Med. Chem., 2009, 52, 3416-3419.
19. Pekala, E.; Marona, H. Estimating the lipophilicity of a number of 2-amino-1-cyclohexanol derivatives exhibiting anticonvulsant activity. Biomed. Chromatogr., 2009, 23, 543-550.
20. Rekka, E.; Retsas, S.; Demopoulos, V.J.; Kourounakis, P.N. Lipophilicity of some substituted morpholine derivatives synthesized as potential antinociceptive agents. Arch. Pharm., 1990, 323, 53-56.
21. Heymans, F.; Le Thérizien, L.; Godfroid, J.J.; Bessin, P. Quantitative structure-activity relationships for N-[N',N'-disubstituted- amino)acetyl]arylamines for local anesthetic activity and acute toxicity. J. Med. Chem., 1980, 23, 184-193.
22. Vistoli, G.; Pedretti, A.; Testa, B. Partition coefficient and molecular flexibility: the concept of lipophilicity space. Chem. Biodivers., 2009, 6, 1152-1169.
23. Ader, R. On the development of psychoneuroimmunology. Eur. J. Pharmacol. 2000, 405, 167-176.
24. Weber, R.J.; Gomez-Flores, R.; Smith, J.E.; Martin, T.J. Neuronal adaptations, neuroendocrine and immune correlates of heroin self- administration. Brain Behav. Immun., 2009, 23, 993-1002.
25. Hadjipetrou-Kourounakis, L.; Karagounis, E.; Rekka, E.; Kourou- nakis, P. Immunosuppression by a novel analgesic-opioid agonist. Scand. J. Immunol., 1989, 29, 449-458.
26. Hadjipetrou-Kourounakis, L.; Rekka, E.; Kourounakis, A. Suppres- sion of adjuvant-induced disease (AID) by a novel analgesic-opioid agonist which also possesses antioxidant activity (neuroimmuno- modulation). Ann. N. Y. Acad. Sci., 1992, 650, 19-24.
27. Labuz, D.; Schmidt, Y.; Schreiter, A.; Rittner, H.L.; Mousa, S.A.; Machelska, H. Immune cell-derived opioids protect against neuropathic pain in mice. J. Clin. Invest., 2009, 119, 278-286.
28. Gavalas, A.; Victoratos, P.; Yiangou, M.; Hadjipetrou- Kourounakis, L.; Rekka, E.; Kourounakis, P. The anti- inflammatory effect of opioids. Int. J. Neurosci., 1994, 74, 259-64.
29. Lambeau, G.; Gelb, M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem., 2008, 77, 495-520.
30. Tani, E.; Rekka, E.; Kourounakis, P.N. Synthesis and effect on free radical processes of some substituted morpholine derivatives with potential biologic activity. Arzneim.-Forsch. Drug Res., 1994, 44, 992-994.
31. Hulsmans, M.; Holvoet, P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell Mol. Med., 2009, 14, 70-8.
32. Chrysselis, M.C.; Rekka, E.A.; Kourounakis, P.N. Hypocholes terolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem., 2000, 43, 609-612.
33. Brown, G.R.; Clarke, D.S.; Foubister, A.J.; Freeman, S.; Harrison, P.J.; Johnson, M.C.; Mallion, K.B.; McCormick, J.; McTaggart, F.; Reid, A.C.; Smith, G.J.; Taylor, M.J. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J. Med. Chem., 1996, 39, 2971-2979.
34. Gutteridge, J.M.; Halliwell, B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N.Y. Acad. Sci., 2000, 899, 136-147.
35. Pepine, C.J. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am. J. Med., 2009, 122, S10-15.
36. Tavridou, A.; Kaklamanis, L.; Megaritis, G.; Kourounakis, A.P.; Papalois, A.; Roukounas, D.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopoulos, V.G. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur. J. Pharmacol., 2006, 535, 34-42.
37. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A.P.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopoulos, V.G. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzo- xazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J. Pharmacol. Exp. Ther., 2007, 323, 794-804.
38. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A.P.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopou- los, V.G. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J. Cardiovasc. Pharmacol., 2008, 51, 573-580.
39. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
40. Roman, R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev., 2002, 82, 131-185.
41. Cowart, L.A.; Wei, S.; Hsu, M.H.; Johnson EF, Krishna MU, Falck JR, Capdevila JH. The CYP4A isoforms hydroxylate epoxyeicosa- trienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J. Biol. Chem., 2002, 277, 35105-35112.
42. Smith, W.L.; Garavito, R.M.; DeWitt, D.L. Prostaglandin endoper- oxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem., 1996, 271, 33157-33160.
43. Brash, A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem., 1999, 274, 23679-23682.
44. Chrysselis, M.C.; Rekka, E.A.; Kourounakis, P.N. Cytochrome P450 modification by a new oxazine derivative with hypolipidemic activity. Res. Commun. Mol. Pathol. Pharmacol., 2000, 108, 325-331.
45. Rekka, E.A.; Kourounakis, A.P.; Avramidis, N.; Kourounakis, P.N. Effect of some biologically interesting substituted tetrahydro-1,4-oxazines on drug metabolising enzymes and on inflammation. Curr. Drug Metab., 2005, 6, 481-485.